Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Neurocrine Bioscienc (NBIX)
Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,985,850
  • Shares Outstanding, K 97,652
  • Annual Sales, $ 1,489 M
  • Annual Income, $ 154,500 K
  • 60-Month Beta 0.46
  • Price/Sales 7.55
  • Price/Cash Flow 64.80
  • Price/Book 6.08
Trade NBIX with:

Options Overview Details

View History
  • Implied Volatility 27.41% ( +0.34%)
  • Historical Volatility 26.27%
  • IV Percentile 18%
  • IV Rank 24.84%
  • IV High 51.08% on 10/20/22
  • IV Low 19.58% on 08/30/23
  • Put/Call Vol Ratio 2.05
  • Today's Volume 58
  • Volume Avg (30-Day) 341
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 12,203
  • Open Int (30-Day) 10,682

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate 0.89
  • Number of Estimates 11
  • High Estimate 1.07
  • Low Estimate 0.27
  • Prior Year 0.69
  • Growth Rate Est. (year over year) +28.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.44 +5.69%
on 08/30/23
119.29 -5.69%
on 09/12/23
+5.61 (+5.25%)
since 08/29/23
3-Month
93.28 +20.60%
on 07/07/23
119.29 -5.69%
on 09/12/23
+18.01 (+19.06%)
since 06/29/23
52-Week
89.04 +26.35%
on 05/30/23
129.29 -12.99%
on 12/01/22
+9.74 (+9.48%)
since 09/29/22

Most Recent Stories

More News
3 A-Rated Pharma Buys for October

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks...

AZN : 67.72 (+0.44%)
NBIX : 112.50 (-2.31%)
NVO : 90.94 (-0.63%)
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the...

NBIX : 112.50 (-2.31%)
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...

NBIX : 112.50 (-2.31%)
3 A-Rated Pharma Stocks to Buy Today

The pharmaceutical industry is expected to grow in the upcoming years, propelled by continual advancements in medicine, aiming to meet the escalating demands for chronic disease treatment and address the...

ABBV : 149.06 (-2.10%)
NBIX : 112.50 (-2.31%)
NVO : 90.94 (-0.63%)
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the...

NBIX : 112.50 (-2.31%)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

NBIX : 112.50 (-2.31%)
3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors...

AMGN : 268.76 (-0.76%)
GSK : 36.25 (-0.25%)
HZNP : 115.69 (unch)
NBIX : 112.50 (-2.31%)
PPH : 79.86 (-0.16%)
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano, Chief Business...

NBIX : 112.50 (-2.31%)
Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine)

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of...

NBIX : 112.50 (-2.31%)
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of...

NBIX : 112.50 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 117.81
2nd Resistance Point 116.65
1st Resistance Point 114.57
Last Price 112.50
1st Support Level 111.34
2nd Support Level 110.19
3rd Support Level 108.11

See More

52-Week High 129.29
Fibonacci 61.8% 113.91
Last Price 112.50
Fibonacci 50% 109.16
Fibonacci 38.2% 104.42
52-Week Low 89.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar